Home > News > Industry > Pharma News > Sukoon Health to infuse...

Sukoon Health to infuse Rs 100 crore for 4 health centres across India by 2023 end

By - Ruchika Sharma
Published On 2020-11-23 07:08 GMT   |   Update On 2021-11-22 17:12 GMT

Delhi: Mental healthcare provider Sukoon Health is planning to invest over Rs 100 crore to open four centres in the country by the end of 2023 as part of its expansion plans, a top company official said. The company currently has a tie up with Fortis Healthcare for its Gurugram-based super specialty hospital which has three psychiatric ICUs."We will plan to add 200 more beds by the end of 2023...

Login or Register to read the full article
Register Now

Delhi: Mental healthcare provider Sukoon Health is planning to invest over Rs 100 crore to open four centres in the country by the end of 2023 as part of its expansion plans, a top company official said. The company currently has a tie up with Fortis Healthcare for its Gurugram-based super specialty hospital which has three psychiatric ICUs.

"We will plan to add 200 more beds by the end of 2023 as part of expansion and create Sukoon Health Centres across India," Sukoon Health MD Vidit Bahri told. As part of the plan, Sukoon Health Mohali centre in Punjab will be launched by 2021-end, which will be a 50-bedded centre and Kolkata centre by the end of 2022 which would also be a 50-bedded facility, he added. Bahri, however, did not disclose the locations of other two centres.
When asked about the investment the company will be making for the expansion and their plans to fund it, Bahri said, "The company will be making close to USD 15 million (over Rs 100 crore) for the expansion, and it will be funded through personal and VC finance". On the company's relationship with Fortis Healthcare, he said, "We have an operations and management partnership with Fortis Healthcare".
Read also: Sri Lanka Govt to establish pharma manufacturing zone


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Caplin Point gets Colombia nod for Softgel Capsules division
AstraZeneca concludes equity investment agreement with Cellectis
Alembic Pharma gets USFDA EIR for Panelav Oncology formulation facility
Cipla, Glenmark recall products from American market over manufacturing issues
Bharat Biotech International Gets CDSCO Panel Nod to Study Mycobacterium Tuberculosis Live Attenuated Vaccine
JnJ submits regulatory applications to EMA for Tremfya for treatment of patients with ulcerative colitis, Crohn's disease
Sentynl Therapeutics, a Zydus company acquires Zokinvy for Progeria from Eiger Biopharma
Walgreens, Boehringer Ingelheim partner to improve diversity in clinical trials